Selinexor: Targeting a novel pathway in multiple myeloma

Selinexor is an orally bioavailable selective inhibitor of nuclear export compound that inhibits exportin‐1 (XPO1), a novel therapeutic target that is overexpressed in multiple myeloma (MM) and is responsible for the transport of ∼220 nuclear proteins to the cytoplasm, including tumour suppressor pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Mo, Clifton C., Yee, Andrew J., Midha, Shonali, Hartley‐Brown, Monique A., Nadeem, Omar, O'Donnell, Elizabeth K., Bianchi, Giada, Sperling, Adam S., Laubach, Jacob P., Richardson, Paul G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435704/
https://www.ncbi.nlm.nih.gov/pubmed/37601856
http://dx.doi.org/10.1002/jha2.709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435704/
https://www.ncbi.nlm.nih.gov/pubmed/37601856
http://dx.doi.org/10.1002/jha2.709

Ejemplares similares